8-K: Pulse Biosciences Enrolls First Patient in NANOCLAMP AF Trial

Pulse Biosciences announced the enrollment of the first patient in its NANOCLAMP AF clinical trial, evaluating its nPulse Cardiac Surgical System for atrial fibrillation.

Summary

• Pulse Biosciences, Inc. (Nasdaq: PLSE) announced the enrollment of the first patient in its NANOCLAMP AF clinical trial on October 24, 2025.
• The NANOCLAMP AF study is a single-arm, prospective multicenter trial designed to demonstrate the safety and effectiveness of the nPulse Cardiac Surgical System for treating atrial fibrillation (AF) during concomitant surgical procedures.
• The first procedure was successfully completed at St. Helena Hospital in St. Helena, California, following recent FDA IDE approval for the system.
• The nPulse Cardiac Surgical System utilizes proprietary Nanosecond Pulsed Field Ablation (nsPFA) energy, a nonthermal energy modality.
• Multiple sites, including two outside the United States, are planned for patient enrollment in the study.
• The nsPFA Cardiac Surgical System received FDA Breakthrough Device Designation in July 2024 and is enrolled in the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP).

Sentiment

Score: 7

Explanation: The announcement of the first patient enrollment in a pivotal clinical trial for a novel technology with FDA Breakthrough Device Designation is a significant positive milestone, indicating progress towards commercialization and addressing a large market. The positive commentary from surgeons further reinforces this. However, it is still an early stage in the trial, and future results are not guaranteed, hence not a 'strong buy' yet.

Positives

• Successful enrollment of the first patient in a pivotal clinical trial marks a significant development milestone for the nPulse Cardiac Surgical System.
• The nPulse Cardiac Surgical System uses a nonthermal mechanism of action, expected to offer an improved safety profile and procedural advantages over conventional thermal ablation methods.
• The technology aims to provide faster, safer, and more effective treatment options for patients suffering from atrial fibrillation.
• The nPulse Cardiac Clamp demonstrated ease of use and speed of treatment, exceeding expectations during the first procedure.
• The nsPFA Cardiac Surgical System was granted FDA Breakthrough Device Designation in July 2024, indicating potential for significant clinical benefit and expedited review.
• Enrollment in the FDA's TPLC Advisory Program (TAP) suggests close collaboration with the FDA, potentially streamlining development and review.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the company's control.
• There is no guarantee that early clinical successes will be predictive of the safety and effectiveness of the nPulse Cardiac Surgical System in broader clinical use.
• The effectiveness of the nPulse Cardiac Surgical System to non-thermally clear cells while sparing adjacent noncellular tissue needs to be proven in the trial.
• The potential market opportunities for nsPFA to treat AF and its future growth are subject to uncertainties.
• Future clinical and regulatory initiatives anywhere in the world are subject to various risks and uncertainties.

Future Outlook

The company anticipates that its nPulse technology has the potential to revolutionize concomitant ablation procedures, offering an improved safety profile and enabling consistent, precise, contiguous, and durable full-thickness lesions in a fraction of the time compared to existing technology. This is expected to translate to improved patient outcomes and expand treatment access. Proving the benefits of nsPFA in the NANOCLAMP AF study could drive significant future adoption of surgical cardiac ablation and advance the standard of care for AF.

Management Comments

• Dr. Gan Dunnington, Cardiothoracic Surgeon for Adventist Health, stated: "After years of development, it is an honor to perform the first NANOCLAMP AF surgical procedure in the U.S. for the treatment of AF using nanosecond PFA... I'm excited for my fellow surgeon colleagues to experience this technology as we aim to bring faster, safer, and more effective treatment options to patients suffering from AF. While I have seen this technology used in the European clinical experience, my team was impressed by the nPulse Cardiac Clamp's ease of use, and the speed of treatment exceeded their expectations."
• Dr. Matthew Romano, National Principal Investigator and Professor of Cardiac Surgery at the University of Michigan, commented: "This trial marks a pivotal moment in our journey to transform patient care. nPulse technology has the potential to revolutionize how we approach concomitant ablation procedures. This device offers an improved safety profile as a result of the nonthermal mechanism of action while enabling consistent, precise, contiguous and durable full-thickness lesions in a fraction of the time compared to existing technology. This should ultimately translate to improved outcomes for our patients and expand treatment to more people in need."
• Dr. Niv Ad, Chief Scientific Officer, Cardiac Surgery at Pulse Biosciences, said: "Treating our first patient so quickly following the IDE approval demonstrates the excitement about nanosecond PFA among cardiovascular surgeons. Proving the benefits of nsPFA in this study could drive significant future adoption of surgical cardiac ablation. We are grateful to all the clinicians who continue to support our clinical work. Together we are poised to advance the standard of care for AF and increase the number of patients being treated."

Industry Context

The announcement positions Pulse Biosciences at the forefront of innovation in cardiac ablation, particularly for atrial fibrillation. The use of Nanosecond Pulsed Field Ablation (nsPFA) represents a significant departure from conventional thermal ablation methods, potentially addressing limitations related to safety and procedural efficiency. This technology could disrupt the existing market for AF treatment, offering a novel approach that may improve patient outcomes and expand the treatable population, aligning with a broader industry trend towards less invasive and more precise medical interventions.

Comparison to Industry Standards

• The nPulse Cardiac Surgical System's nonthermal mechanism of action is highlighted as a key differentiator, expected to provide significant safety and procedural advantages over conventional thermal ablation methods currently used by competitors.
• Management comments suggest the nPulse Cardiac Clamp's ease of use and speed of treatment exceeded expectations, implying a potential advantage over existing surgical ablation tools.
• The technology aims to create consistent, precise, contiguous, and durable full-thickness lesions in a fraction of the time compared to existing technology, which could set a new benchmark for efficiency in concomitant cardiac procedures.

Stakeholder Impact

• **Shareholders:** Positive impact due to progress in clinical development of a key product, potentially increasing future revenue streams and market valuation. The news could lead to increased investor confidence.
• **Patients:** Potential for improved treatment options for atrial fibrillation, offering a safer, faster, and more effective procedure with better outcomes.
• **Healthcare Providers (Surgeons):** Introduction of a new tool that is described as easy to use and fast, potentially improving surgical efficiency and patient care.
• **Employees:** Positive impact on morale and job security due to company progress and potential for future growth and commercial success.

Next Steps

• Continue patient enrollment in the NANOCLAMP AF clinical trial across multiple sites, including two outside the United States.
• Gather data to demonstrate the safety and effectiveness of the nPulse Cardiac Surgical System for the treatment of atrial fibrillation in concomitant surgical procedures.
• Advance the nPulse technology for use in other select markets, such as surgical soft tissue ablation.

Key Dates

Recommendation

The enrollment of the first patient in a pivotal clinical trial for a novel, FDA Breakthrough designated device is a positive development, demonstrating execution on the company's strategic roadmap. This milestone de-risks the development process to some extent and highlights the potential for a significant market opportunity. However, it is still an early stage in a clinical trial, and the ultimate success and commercial viability of the device are not yet proven. While the long-term outlook appears promising, a 'hold' recommendation is appropriate as investors await further clinical data and regulatory progress before a stronger 'buy' signal emerges. The inherent risks associated with clinical trials and new medical device commercialization warrant a cautious approach at this stage.

Keywords

Pulse Biosciences, NANOCLAMP AF, Atrial Fibrillation, nPulse Cardiac Surgical System, Nanosecond Pulsed Field Ablation, nsPFA, Clinical Trial, Medical Device, Cardiac Ablation, FDA Breakthrough Device, Cardiothoracic Surgery